Ocumetics Technology Corp (OTC) AI Stock Analysis

• Market Cap: C$140.08M
• Dividend Yield: N/A
• Average Volume (3M): 77.99K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.58
• Revenue Growth: N/A
• EPS Growth: -41.53%
• Country: US
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.01
• Shares Outstanding: 52,564,106
• 10 Day Avg. Volume: 70,232
• 30 Day Avg. Volume: 77,988
• PEG Ratio: 0.59
• Price to Book (P/B): -18.55
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -14.28
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: C$0.58 ▲(5.82% Upside)

The score is primarily held down by very weak financial performance (no revenue, ongoing losses, negative equity, and persistent cash burn). Technicals also remain bearish with the stock trading below key moving averages and negative MACD, despite oversold readings. Positive corporate updates around clinical progress and financing provide some support but are not yet reflected in operating fundamentals.

Positive Factors

Product Development

The collaboration with Medicel to optimize lens delivery systems enhances product efficacy, potentially improving market acceptance and competitive positioning in ophthalmic devices.

Clinical Progress

Promising early clinical results for the intraocular lens indicate potential for successful product development, supporting future regulatory approval and market entry.

Financing and Funding

The amended financing terms to raise up to $2.9 million provide necessary capital for clinical trials and R&D, supporting long-term product development and operational goals.

Negative Factors

Financial Performance

The lack of revenue and persistent losses highlight significant financial challenges, limiting the company's ability to self-fund operations and necessitating reliance on external financing.

Balance Sheet Health

Negative equity and rising debt levels indicate a weakened balance sheet, reducing financial flexibility and increasing risk in sustaining long-term operations.

Cash Flow Sustainability

Consistent negative cash flow underscores liquidity pressures, challenging the company's ability to maintain operations without continuous external funding.

Ocumetics Technology Corp Business Overview & Revenue Model

Company Description

Ocumetics Technology Corp., a research and product development company, designs and produces various lenses. Its products include Bionic Lens, an expandable intraocular lens that fits within the natural lens compartment of the eye to eliminate the need for corrective lenses. The company is headquartered in Calgary, Canada.

How the Company Makes Money

Ocumetics Technology Corp generates revenue primarily through the development and sale of its proprietary eye care products. The company's main revenue stream comes from the commercialization of its advanced lens technologies, which are sold to healthcare providers, clinics, and directly to consumers. Ocumetics may also engage in strategic partnerships and licensing agreements with other companies in the healthcare and optical industries, which can provide additional income through royalties or shared revenue models. Furthermore, the company might receive funding and support through research grants or investment from healthcare-focused venture capital firms.

Ocumetics Technology Corp Financial Statement Overview

Summary

Financials are highly stressed: zero revenue across periods, sizable and worsening net losses (TTM net loss ~-$4.2M), rising leverage (~$4.9M debt), and deeply negative equity (~-$3.9M). Cash flow remains consistently negative (TTM FCF ~-$2.43M) with only modest improvement, implying continued reliance on external financing.

Income Statement

Results remain very weak: the company reports zero revenue across the annual periods provided and TTM (Trailing-Twelve-Months), with persistently negative gross profit and large operating losses. Net losses have also remained sizeable (TTM net loss of about $4.2M vs. ~$3.0M in 2024), indicating limited progress toward scale or profitability. A modest positive is that EBITDA loss in TTM (about -$2.9M) is less negative than EBIT (about -$4.2M), but overall the lack of revenue and continued losses drive a low score.

Balance Sheet

Balance sheet risk is elevated. Stockholders’ equity has turned deeply negative (about -$3.9M in TTM vs. -$1.9M in 2024), while total debt has risen to roughly $4.9M in TTM (up from ~$4.0M in 2024). Total assets have also declined versus 2024, reducing financial flexibility. The earlier 2022–2023 period showed positive equity, but the recent shift to negative equity and higher leverage materially weakens the profile.

Cash Flow

Cash burn remains heavy, with operating cash flow negative in every period shown and still about -$2.36M in TTM (Trailing-Twelve-Months). Free cash flow is also consistently negative (about -$2.43M TTM), though TTM free cash flow is slightly improved versus 2024 and the stated free cash flow growth is positive in TTM. A relative strength is that free cash flow roughly tracks net loss (free cash flow to net income ~1.03 in TTM), but overall liquidity pressure remains high given sustained outflows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-69.94K	-134.30K	-117.62K	-102.21K	-96.18K	0.00
EBITDA	-2.85M	-2.29M	-3.50M	-2.09M	-3.42M	-99.35K
Net Income	-4.24M	-3.02M	-3.64M	-2.22M	-598.19K	-172.49K
Balance Sheet
Total Assets	1.63M	2.32M	1.04M	1.37M	825.25K	225.32K
Cash, Cash Equivalents and Short-Term Investments	905.41K	1.57M	235.83K	602.09K	83.90K	224.35K
Total Debt	4.92M	3.95M	321.64K	292.34K	0.00	0.00
Total Liabilities	5.52M	4.26M	945.33K	536.45K	1.10M	17.94K
Stockholders Equity	-3.88M	-1.94M	91.10K	837.40K	-270.50K	207.38K
Cash Flow
Free Cash Flow	-2.43M	-2.51M	-2.19M	-1.69M	-213.63K	-817.00
Operating Cash Flow	-2.36M	-2.43M	-2.05M	-1.62M	-89.13K	-817.00
Investing Cash Flow	-109.77K	-1.46M	-142.17K	-66.82K	-214.92K	0.00
Financing Cash Flow	1.37M	3.85M	1.82M	444.35K	387.11K	0.00

Ocumetics Technology Corp Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OTC, the sentiment is Negative. The current price of 0.55 is below the 20-day moving average (MA) of 0.60, below the 50-day MA of 0.70, and below the 200-day MA of 0.69, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 45.00 is Neutral, neither overbought nor oversold. The STOCH value of 33.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:OTC.

Ocumetics Technology Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COV	53 Neutral	C$45.24M	21.97	7.07%	―	5.29%	-29.02%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VPT	50 Neutral	C$21.15M	-5.04	―	―	28.59%	23.46%
ASG	46 Neutral	C$22.25M	-11.78	-31.12%	―	9.71%	-118.02%
PINK	46 Neutral	C$27.12M	-1.22	-181.70%	―	209.29%	35.38%
OTC	44 Neutral	C$140.08M	-17.38	―	―	―	-41.53%

Ocumetics Technology Corp Corporate Events

Ocumetics Replaces Chief Medical Officer Role With Scientific Advisory Committee Ahead of Pivotal Trial

Ocumetics Technology Corp., a leader in next-generation ophthalmic technology, is restructuring its medical and clinical leadership as it advances its accommodating intraocular lens through early feasibility studies toward late-stage clinical development. The company will replace its single Chief Medical Officer role, currently held under a consulting agreement by Dr. Doyle Stulting, with a multi-member Scientific Advisory Committee composed of internationally recognized experts in ophthalmology, medical research, and lens science, to provide broader medical, clinical and regulatory oversight ahead of a planned pivotal FDA clinical trial expected in 2027, while acknowledging Dr. Stulting’s contributions and reaffirming its focus on executing its clinical and regulatory strategy for global commercialization.

The most recent analyst rating on (TSE:OTC) stock is a Hold with a C$0.58 price target. To see the full list of analyst forecasts on Ocumetics Technology Corp stock, see the TSE:OTC Stock Forecast page.

Ocumetics Raises Over $1 Million to Advance First-in-Human Clinical Trials

Ocumetics Technology Corp. has closed the first tranche of a brokered private placement and a concurrent non-brokered placement, raising total gross proceeds of approximately $1.02 million through the sale of 1,706,383 units at $0.60 per unit, each unit comprised of one common share and one warrant exercisable at $0.75 until late 2028. The funds are earmarked primarily to support the company’s first-in-human clinical trials, ongoing R&D and general corporate purposes, with the offering led by Centurion One Capital and involving participation by several directors, underscoring insider support as Ocumetics advances its clinical and commercialization trajectory in the ophthalmic technology space.

The most recent analyst rating on (TSE:OTC) stock is a Hold with a C$0.58 price target. To see the full list of analyst forecasts on Ocumetics Technology Corp stock, see the TSE:OTC Stock Forecast page.

Ocumetics Amends Terms of Brokered Financing to Raise Up to $2.9 Million

Ocumetics Technology Corp. has amended the terms of its previously announced brokered private placement led by Centurion One Capital, now planning to issue up to 4,166,666 units at $0.60 per unit for gross proceeds of up to $2.5 million, with each unit comprising one common share and a three-year warrant exercisable at $0.75. The company has also granted the lead agent an option to sell an additional 625,000 units for up to $375,000, expects to close the financing around December 29, 2025 subject to regulatory approvals, and intends to use the proceeds primarily to fund first-in-human clinical trials, ongoing R&D and general corporate purposes, with potential insider participation under related-party transaction exemptions.

Ocumetics and Medicel Collaborate on Enhanced Lens Delivery System

Ocumetics Technology Corp. has announced an optimized lens delivery system developed in collaboration with Medicel AG, a leader in ophthalmic device delivery systems. This enhancement, based on surgeon feedback from initial human implantations, aims to improve loading efficiency and streamline implantation procedures, facilitating the acceptance of Ocumetics’ intraocular lens as the company prepares for expanded clinical studies in early 2026. This development underscores Ocumetics’ commitment to advancing its accommodating intraocular lens technology, potentially impacting its market positioning and stakeholder engagement as it moves towards regulatory engagements and broader trials.

Ocumetics Technology Corp. Launches $2.5 Million Private Placement to Fund Clinical Trials

Ocumetics Technology Corp. has announced a brokered private placement led by Centurion One Capital to raise $2.5 million through the sale of units, each consisting of a common share and a warrant. The funds are intended to support the company’s first-in-human clinical trials, ongoing research and development, and general corporate purposes. This strategic move is expected to bolster Ocumetics’ financial position and advance its clinical initiatives, potentially enhancing its market presence in the medical technology sector.

Ocumetics Reports Promising Early Results in Intraocular Lens Study

Ocumetics Technology Corp. announced promising one-month results from its first-in-human clinical study of the Ocumetics Accommodating Intraocular Lens. The initial group of patients showed significant improvement in vision, surpassing expectations with Corrected Distance Visual Acuity ranging from 20/32 to 20/25. These results reinforce the potential of the Ocumetics Lens to restore vision without corrective lenses and support the company’s advancement to the next phases of clinical trials.